4.Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma: Editorial on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”
Junlong DAI ; Jimmy Che-To LAI ; Grace Lai-Hung WONG ; Terry Cheuk-Fung YIP
Clinical and Molecular Hepatology 2024;30(4):698-701
5.Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma: Editorial on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”
Junlong DAI ; Jimmy Che-To LAI ; Grace Lai-Hung WONG ; Terry Cheuk-Fung YIP
Clinical and Molecular Hepatology 2024;30(4):698-701
6.Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma: Editorial on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”
Junlong DAI ; Jimmy Che-To LAI ; Grace Lai-Hung WONG ; Terry Cheuk-Fung YIP
Clinical and Molecular Hepatology 2024;30(4):698-701
7.Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma: Editorial on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”
Junlong DAI ; Jimmy Che-To LAI ; Grace Lai-Hung WONG ; Terry Cheuk-Fung YIP
Clinical and Molecular Hepatology 2024;30(4):698-701
8.Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?”
Dorothy Cheuk-Yan YIU ; Huapeng LIN ; Vincent Wai-Sun WONG ; Grace Lai-Hung WONG ; Ken LIU ; Terry Cheuk-Fung YIP
Clinical and Molecular Hepatology 2024;30(4):970-973
9.Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present andfuture
Terry Cheuk-Fung YIP ; Fei LYU ; Huapeng LIN ; Guanlin LI ; Pong-Chi YUEN ; Vincent Wai-Sun WONG ; Grace Lai-Hung WONG
Clinical and Molecular Hepatology 2023;29(Suppl):S171-S183
Inflammation is the key driver of liver fibrosis progression in non-alcoholic fatty liver disease (NAFLD). Unfortunately, it is often challenging to assess inflammation in NAFLD due to its dynamic nature and poor correlation with liver biochemical markers. Liver histology keeps its role as the standard tool, yet it is well-known for substantial sampling, intraobserver, and interobserver variability. Serum proinflammatory cytokines and apoptotic markers, namely cytokeratin-18, are well-studied with reasonable accuracy, whereas serum metabolomics and lipidomics have been adopted in some commercially available diagnostic models. Ultrasound and computed tomography imaging techniques are attractive due to their wide availability; yet their accuracies may not be comparable with magnetic resonance imaging-based tools. Machine learning and deep learning models, be they supervised or unsupervised learning, are promising tools to identify various subtypes of NAFLD, including those with dominating liver inflammation, contributing to sustainable care pathways for NAFLD.
10.Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?”
Dorothy Cheuk-Yan YIU ; Huapeng LIN ; Vincent Wai-Sun WONG ; Grace Lai-Hung WONG ; Ken LIU ; Terry Cheuk-Fung YIP
Clinical and Molecular Hepatology 2024;30(4):970-973